Cancer chemotherapy associated nausea and vomiting therapeutics are drugs that help reduce nausea and vomiting due to chemotherapy. These drugs prevent and treat nausea and vomiting caused by chemotherapy and help improve quality of life for cancer patients.

One of the key trends in the cancer chemotherapy associated nausea and vomiting therapeutics market is the rise in oral fixed-dose combination drugs. Fixed-dose combination drugs deliver multiple antiemetic agents in a single oral dosage form. This increases patient compliance and convenience. Some examples of oral fixed-dose combinations are Emend (aprepitant) capsules, SUSTOL (granisetron) extended-release injection, and NEPA (netupitant-palonosetron) capsules. These drug combinations are driving the growth of the market.

The global cancer chemotherapy associated nausea and vomiting therapeutics market is dominated by the antiemetics sub-segment, which accounts for nearly 60% share of the overall market. The high adoption of antiemetics drugs for the prevention and treatment of nausea and vomiting caused due to chemotherapy is the major factor responsible for the dominant share of this sub-segment.

The Global Cancer Chemotherapy Associated Nausea And Vomiting Therapeutics Market Size is expected to witness high growth, exhibiting CAGR of 5.7% over the forecast period, due to increasing prevalence of cancer worldwide.

North America region currently dominates the global market and is expected to retain its dominance over the forecast period. This is attributed to the growing number of cancer patients being treated through chemotherapy and rising healthcare expenditure in the region. Asia Pacific region is expected to witness the fastest growth rate over the forecast period owing to increasing cancer awareness initiatives by public and private organizations.

Key players operating in the cancer chemotherapy associated nausea and vomiting therapeutics market are Johnson & Johnson Services, Inc., Teleflex Incorporated, Cooper Surgical, Inc., Genicon, Medtronic, B. Braun SE. The companies are focusing on developing innovative treatment options to cater to the growing demand and consolidate their market position. For instance, Johnson & Johnson Services, Inc. launched Dificid in 2008 for treatment of Clostridium difficile-associated diarrhea.

Read more

https://healthcarelatesteditionnews.blogspot.com/2023/11/nausea-and-vomiting-therapeutics-is.html